Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 5—May 2007

Letter

Extensively Drug-resistant Tuberculosis, Italy and Germany

Giovannittista Migliori*Comments to Author , Johannes Ortmann†, Enrico Girardi‡, Giorgio Besozzi§, Christoph Lange¶, Daniela Cirillo#, M. Ferrarese**, Giuseppina De Iaco††, Andrea Gori‡‡, Mario.C. Raviglione§§, and SMIRA/TBNET Study Group
Author affiliations: *Salvatore Maugeri Foundation, Tradate, Italy; †Bad Lippspringe Hospital, Germany; ‡Ospedale Lazzaro Spallanzani, Rome, Italy; §Eugenio Morelli Hospital, Sondalo, Italy; ¶Research Center Borstel, Borstel, Germany; #S. Raffaele Institute, Milan, Italy; **Niguarda Hospital, Milan, Italy; ††University of Brescia, Brescia, Italy; ‡‡University of Milan, Milan, Italy; §§World Health Organization, Geneva, Switzerland

Main Article

Table A1

XDR TB patient characteristics, Italy and Germany, 2003–2006*

Age (y), sex Country
Radiologic cavities, thorax† No. treatment periods‡ Drugs received§ Drug resistance†§ Hospitalization, d Smear conversion, d Culture conversion, d Treatment duration, mo Outcome¶
Of diagnosis Of birth
40, M Italy Italy Bilateral 3 S, R, H, E, Z; Rb S, R, H, E, Z; FQ, AK, Cyc 220 73 Improved
61, F Italy Peru Monolateral 1 S, R, H, E, Z; FQ, Eth, Ak, PAS, Cyc S, R, H, E, Z; FQ, AK, Cyc 83 16 Died
27, F Italy Moldova Monolateral 3 S, R, H, E, Z; FQ Eth AK, PAS, K,Cyc, Clof S, R, H, Z; FQ, Eth, K 406 300 300 10 Improved
46, M Italy Senegal Bilateral 4 S, R, H, E, Z; FQ, PAS, Cyc S, R, H, Z; FQ, Eth, AK, PAS 69 49 35 6 Improved
43, F Italy Italy Bilateral 3 S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof 422 94 Died
38, F Italy Italy Bilateral 3 S, R, H, E, Z; FQ, Eth, PAS, C, Cyc S, R, H, E, Z; FQ, AK, PAS, Cyc 80 12 Died
49, F Italy Italy Bilateral 3 S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th S, R, H, E, Z; FQ, Eth, AK, PAS, C, K, Cyc, Rb, Clof, Dap, Cl, Th 625 60 Died
33, M Germany Uzbekistan Monolateral 2 S, R, H, E, Z S, R, H, E, Z; FQ, Eth, AK, C, Rb 120 4 Improved
29, M Germany Uzbekistan Bilateral 2 S, R, H, E, Z; Rb S, R, H, E, Z; FQ, C 240 180 160 12 Improved
52, M Germany Azerbaijan Monolateral >1 Not available S, R, H, E, Z; FQ, AK, PAS, C, Cyc, Rb 140 7 35 6 Improved
36, F Italy Romania Bilateral 4 S, R, H, E, Z; FQ, Eth, PAS, Cyc, Rb R, H, Z; FQ, AK, Rb 248 110 28 Improved

*XDR TB, extensively drug-resistant tuberculosis; –, not achieved. All patients were HIV seronegative.
†At time of XDR TB diagnosis.
‡Treatment periods >30 d.
§First-line drugs: S, streptomycin; R, rifampin: H, isoniazid, E, ethambutol; Z, pyrazinamide; second-line drugs: FQ, fluoroquinolone; Eth, ethionamide; AK, amikacin; PAS, para-aminosalycilic acid; C, capreomycin; K, kanamycin; Cyc, cycloserine; other drugs: Rb, rifabutin; Clof, clofazimine; Dap, dapsone; Cl, clarithromycin; Th, thiacetazone.
¶Improved, achieved bacteriologic conversion, radiologic and clinical improvement, or both.

Main Article

1Members of the SMIRA (Multicenter Italian Study on Resistance to Anti-tuberculosis Drugs)/TBNET (Tuberculosis Network in Europe Trials): Detlef Kirsten, Sabine Ruesch-Gerdes, Federica Piana, Luigi R. Codecasa, Carla Lacchini, Alberto Matteelli, Saverio De Lorenzo, Panaiota Troupioti, Gina Gualano, Patrizia De Mori, Lanfranco Fattorini, Elisabetta Iona, Giovanni Ferrara, and Rosella Centis

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO